ITRM 1.19 Iterum Therapeutics plc
| Range: | 0.622-2.5 | Vol Avg: | 282271 | Last Div: | 0 | Changes: | 0.08 |
| Beta: | 2.25 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri May 25 2018 | Empoloyees: | 14 | ||
| CUSIP: | G6333L101 | CIK: | 0001659323 | ISIN: | IE000TTOOBX0 | Country: | IE |
| CEO: | Mr. Corey N. Fishman | Website: | https://www.iterumtx.com | ||||
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow